Moderna Targets Rare Ebola Virus

Moderna’s racing to develop an mRNA vaccine for Bundibugyo virus—the rare Ebola strain fueling a deadly outbreak in DRC and Uganda—with early human trials possible in months, backed by CEPI. This urgent push highlights a critical gap: while we’ve prioritized common Ebola strains, rarer but equally lethal variants like Bundibugyo can’t be ignored. Leveraging mRNA’s speed, Moderna can rapidly adapt its platform by swapping genetic code—unlike traditional methods. CEPI is also funding two other vaccine candidates using different tech to boost success odds. Though this won’t stop the current outbreak, it’s a vital step toward future preparedness. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f36dbd7b59b9a385